Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Gets Non-Hodgkin’s Lymphoma Candidate With Seattle Genetics Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

SGN-40 will be examined for potential use with and without Rituxan.
Advertisement

Related Content

Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Seattle Genetics CEO Clay Siegall: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Seattle Genetics Seeks To “Change The Treatment Paradigm” For Non-Hodgkin’s Lymphoma
Seattle Genetics Seeks To “Change The Treatment Paradigm” For Non-Hodgkin’s Lymphoma
Astellas' Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Astellas’ Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims
Astellas’ Once-Daily Prograf Receives Mixed Decisions For Three Prophylaxis Claims

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

PS065143

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel